Shanghai Fosun Pharmaceutical (Group) Company Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shanghai Fosun Pharmaceutical (Group) Company Limited with three other
companies in this sector in China:
Shenzhen Neptunus Bioengineer
sales of 11.12 billion Chinese Renmimbi [US$1.65 billion]
of which 85%
was Pharmaceutical Distribution),
Beijing Tongrentang Co., Ltd.
(10.79 billion Chinese Renmimbi [US$1.60 billion]
of which 51%
was Manufacturing), and
Tasly Pharmaceutical Group Company Limited
(13.22 billion Chinese Renmimbi [US$1.96 billion]
of which 51%
was Medicine Commerce).
During the year ended December of 2015, sales at
Shanghai Fosun Pharmaceutical (Group) Company Limited were 12.50 billion Chinese Renmimbi (US$1.85 billion).
increase of 4.7%
versus 2014, when the company's sales were 11.94 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Shanghai Fosun Pharmaceutical (Group) Company Limited
(and since 2010, sales have increased a total of 175%).
Sales of Other Business Operations saw an increase
that was more than double the company's growth rate: sales were up
163.7% in 2015, from
14.33 million Chinese Renmimbi to 37.78 million Chinese Renmimbi.
Shanghai Fosun Pharmaceutical (Group) Company Limited also saw significant increases in sales in
Pharmaceutical Manufacturing and R&d (up 21.7% to 8.84 billion Chinese Renmimbi)
Medical Diagnosis and Medical Devices (up 16.2% to 2.24 billion Chinese Renmimbi)